Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-09-21
2009-12-08
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C548S468000, C514S414000, C514S323000, C544S144000, C546S187000
Reexamination Certificate
active
07629339
ABSTRACT:
Alkoxy indolinone based acid and amide derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.
REFERENCES:
patent: 6653308 (2003-11-01), Guan et al.
McMahon, et al., “Protein Kinase Inhibitors: Structural Determinants for Target Specificity”Curr. Opin. Drug Disc. Dev. 1: 131-146 (1998).
Sun, et al., “Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases”,J. Med. Chem. 41: 2588-2603 (1998).
Sun, et al., “Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases”,J. Med. Chem. 42: 5120-5130 (1999).
Laird, et al., “SU6668 Is a Potent Antiangiogenic and Antitumor Agent That Induces Regression of Established Tumors”,Cancer Res. 60: 4152-4160 (2000).
Smolich, et al., “The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts”,Blood 97: 1413-1421 (2001).
Laird, et al., “SU6668 inhibits Flk-1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice”,FASEB J. 16: 681-690 (2002).
Mendel, et al., “In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship”,Clin. Cancer Res. 9: 327-337 (2003).
Sun, et al., “Discovery of 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase”,J. Med. Chem. 46: 1116-1119 (2003).
Feng Yangbo
Liang Congxin
Anderson Rebecca L
Schwegman Lundberg & Woessner, P.A.
The Scripps Research Institute
LandOfFree
Alkoxy indolinone based protein kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alkoxy indolinone based protein kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alkoxy indolinone based protein kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4086864